



FOR IMMEDIATE RELEASE

Contacts: Stephanie Euler/Joan Vander Valk  
Stern + Associates for Fujirebio  
(908) 276-4344  
stephanie@sternassociates.com  
joan@sternassociates.com

Ronald L. Weiss, M.D., M.B.A.  
President and Chief Operating Officer  
ARUP Laboratories  
(801) 584-5188

**Fujirebio Diagnostics and ARUP Laboratories Sign Exclusive Agreement for  
MESOMARK® Testing**  
*Mesothelioma Patients Can Be Monitored Through a Simple Blood Sample*

**MALVERN, Pa. and SALT LAKE CITY, February 12, 2007** – Marking a new era in mesothelioma testing, Fujirebio Diagnostics, Inc. (FDI) and ARUP Laboratories (ARUP) have signed an exclusive agreement to offer the MESOMARK® Assay, the world's first *in-vitro* test for monitoring mesothelioma, a form of cancer linked to asbestos exposure. Beginning on February 26, all MESOMARK patient samples will be tested by ARUP, leveraging the company's highly complex and unique medical testing capabilities. ARUP processes more than 25,000 specimens of blood, body fluid, and tissue biopsies per day for clients located throughout the United States.

“ARUP Laboratories is a highly respected national reference laboratory with an extensive test menu in clinical and anatomic pathology, covering more than half of today's national teaching and children's hospitals, large commercial laboratories, military and government facilities, and major clinics,” said Monte Wiltse, vice president of sales and marketing for Fujirebio Diagnostics. “By partnering with ARUP, we're ensuring that this test is available to the largest and broadest audience, providing the best possible services for all physicians and their patients, and the means to improve cancer outcomes.”

Between 1979 and 2001, at least 43,000 people died from mesothelioma, according to the Environmental Working Group. This number could be even higher, since this type of cancer is often misdiagnosed and has only been tracked as a cause of death since 1999. The MESOMARK Assay test kit was developed by Fujirebio Diagnostics to monitor patients confirmed as having mesothelioma, for recurrence in patients following surgery, or for measuring response to therapies. Using the MESOMARK test results in conjunction with other clinical and laboratory data may help physicians determine the appropriate therapy by detecting disease progression. MESOMARK received approval from the U.S. Food & Drug Administration (FDA) under the Humanitarian Device Exemption (HDE) program on January 24, 2007.

-more-

“Fujirebio Diagnostics’ MESOMARK Assay will now enable physicians to monitor the progress of their patients diagnosed with mesothelioma,” said Ronald L Weiss, M.D., president and COO of ARUP Laboratories. “The ability to track this aggressive form of cancer with a blood test is a welcome addition to ARUP Laboratories’ comprehensive menu of services and to the armamentarium of physicians treating this serious disease.”

Mesothelioma affects the sac lining the chest, the abdominal cavity or the area around the heart. Many people with this cancer have been employed in environments where they inhaled asbestos, such as in the shipbuilding and construction industries. Most insulation and construction materials manufactured before the mid-1970s contained asbestos, including insulation on pipes and boilers; fireproofing spray; roof, floor, and ceiling tiles; and automobile brakes and clutches. Currently, more than 100 million people worldwide have been exposed to asbestos through their professions over the years – often unknowingly – including shipyard workers, insulators, boilermakers, plumbers and maintenance workers.

#### **About Fujirebio Diagnostics, Inc.**

Fujirebio Diagnostics, Inc. is a premier diagnostics company and the industry leader in biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of *in-vitro* diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is a wholly owned subsidiary of Fujirebio Inc. Fujirebio Inc. is a leading healthcare company in Japan with a focus on diagnostics, and is a group company of Miraca Holdings. Fujirebio Diagnostics has a worldwide distribution network which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call 610-240-3800 or visit [www.fdi.com](http://www.fdi.com).

#### **About ARUP Laboratories**

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With more than 1,900 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients throughout the United States. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP’s clients include more than half of the nation's university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology™. Further information on ARUP Laboratories can found at [www.aruplab.com](http://www.aruplab.com).